Loading clinical trials...
Loading clinical trials...
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0001
Beijing, Beijing Municipality, China
Local Institution - 0007
Beijing, Beijing Municipality, China
Local Institution - 0014
Beijing, Beijing Municipality, China
Local Institution - 0008
Chongqing, Chongqing Municipality, China
Local Institution - 0011
Wuhan, Hubei, China
Local Institution - 0016
Wuhan, Hubei, China
Local Institution
Changsha, Hunan, China
Local Institution
Nanjing, Jiangsu, China
Local Institution - 0002
Changchun, Jilin, China
Local Institution - 0006
Dalian, Liaoning, China
Start Date
November 25, 2019
Primary Completion Date
March 8, 2021
Completion Date
January 7, 2022
Last Updated
March 8, 2023
220
ACTUAL participants
BMS-986165
DRUG
Placebo
OTHER
Lead Sponsor
Bristol-Myers Squibb
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions